Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity

Haematologica

Volumn 97, Issue 3, 2012, Pages 371-378

  Thathia, Shabnam H ^a   Ferguson, Stuart ^a   Gautrey, Hannah E ^a   van Otterdijk, Sanne D ^a   Hili, Michela ^a   Rand, Vikki ^a   Moorman, Anthony V ^a   Meyer, Stefan ^b   Brown, Robert ^c   Strathdee, Gordon ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Acute lymphoblastic leukemia; DNA methylation; Drug resistance; Epigenetic; TWIST2

Indexed keywords

DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; COMBINED BISULFITE AND RESTRICTION ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; DRUG SENSITIVITY; EPIGENETICS; ETV6 GENE; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE LOSS; GENETIC PROCEDURES; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PYROSEQUENCING; RUNX1 GENE; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TWIST2 GENE;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; TWIST TRANSCRIPTION FACTOR;

EID: 84863244344     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049593     Document Type: Article

References (20)

1. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5):579-87.
2. Plasschaert SL, Kamps WA, Vellenga E, de Vries EG, de Bont ES. Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev. 2004;30(1):37-51.
3. O'Neil J, Look AT. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene. 2007;26 (47):6838-49.
4. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, et al. A twist code determines the onset of osteoblast differentiation. Devel Cell. 2004;6(3):423-35.
5. Gong XQ, Li L. Dermo-1, a multifunctional basic helix-loop-helix protein, represses MyoD transactivation via the HLH domain, MEF2 interaction, and chromatin deacetylation. J Biol Chem. 2002;277(14): 12310-7.
6. Sosic D, Richardson JA, Yu K, Ornitz DM, Olson EN. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell. 2003;112(2):169-80.
7. Lee YS, Lee HH, Park J, Yoo EJ, Glackin CA, Choi YI, et al. TWIST2, a novel ADD1/SREBP1c interacting protein, represses the transcriptional activity of ADD1/SREBP1c. Nuc Acid Res. 2003;31 (24):7165-74.
8. Murakami M, Ohkuma M, Nakamura M. Molecular mechanism of transforming growth factor-beta-mediated inhibition of growth arrest and differentiation in a myoblast cell line. Dev Growth Differ. 2008;50(2):121-30.
9. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005;23 (17):3877-85.
10. Sharabi AB, Aldrich M, Sosic D, Olson EN, Friedman AD, Lee SH, et al. Twist-2 controls myeloid lineage development and function. PLoS Biol. 2008;6(12):e316.
11. Costello JF, Plass C. Methylation matters. J Med Genet. 2001;38(5):285-303.
12. Slany RK. When epigenetics kills: MLL fusion proteins in leukemia. Hematol Oncol. 2005;23(1):1-9.
13. Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res. 2007;13(17):5048-55.
14. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nuc Acid Res. 1997;25(12):2532-4.
15. Zelent A, Greaves M, Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene. 2004;23 (24):4275-83.
16. Weston VJ, Austen B, Wei W, Marston E, Alvi A, Lawson S, et al. Apoptotic resistance to ionizing radiation in pediatric Bprecursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling. Blood. 2004; 104(5):1465-73.
17. Blyth K, Slater N, Hanlon L, Bell M, Mackay N, Stewart M, et al. Runx1 promotes B-cell survival and lymphoma development. Blood Cells Mol Dis. 2009;43(1): 12-9.
18. Cameron ER, Neil JC. The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene. 2004;23(24):4308-14.
19. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115-36.
20. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33-40.